Navigation Links
CWRU School of Medicine researchers discover gene that permanently stops cancer cell proliferation
Date:7/31/2012

Researchers at Case Western Reserve University School of Medicine have discovered a mutant form of the gene, Chk1, that when expressed in cancer cells, permanently stopped their proliferation and caused cell death without the addition of any chemotherapeutic drugs. This study illustrates an unprecedented finding, that artificially activating Chk1 alone is sufficient to kill cancer cells.

"We have identified a new direction for cancer therapy and the new direction is leading us to a reduction in toxicity in cancer therapy, compared with chemotherapy or radiation therapy," said Dr. Zhang, assistant professor, Department of Pharmacology at the School of Medicine, and member of the university's Case Comprehensive Cancer Center. "With this discovery, scientists could stop the proliferation of cancer cells, allowing physicians time to fix cells and genetic errors."

While studying the basic mechanisms for genome integrity, Dr. Zhang's team unexpectedly discovered an active mutant form of human Chk1, which is also a non-natural form of this gene. This mutation changed the protein conformation of Chk1 from the inactive form into an active form. Remarkably, the research team discovered that when expressed in cancer cells, this active mutant form of Chk1 permanently stopped cancer cell proliferation and caused cell death in petri dishes even without the addition of any chemotherapeutic drugs.

The biggest advantage of this potential strategy is that no toxic chemotherapeutic drug is needed to achieve the same cancer killing effect used with a combination of Chk1 inhibitors and chemotherapeutic drugs.

Cells respond to DNA damage by activating networks of signaling pathways, termed cell cycle checkpoints. Central to these genome pathways is the protein kinase, called Chk1. Chk1 facilitates cell survival, including cancer cells, under stressful conditions, such as those induced by chemotherapeutic agents, by placing a temporary stop on the cell cycle progression and coordinating repair programs to fix the DNA errors.

It has long been suggested that combining Chk1 inhibition with chemotherapy or radiotherapy should significantly enhance the anticancer effect of these therapies. This idea has serves as the basis for multiple pharmaceutical companies searching for potential Chk1 inhibitors that can effectively combine with chemotherapy in cancer therapy. To date, no Chk1 inhibitor has passed the clinical trial stage III . This led Dr. Zhang's team to look for alternative strategies for targeting Chk1 in cancer therapy.

Future research by Dr. Zhang and his team will consider two possible approaches to artificially activating Chk1 in cancer cells. One possibility is to use the gene therapy concept to deliver the active mutant form of Chk1 that the team discovered, into cancer cells. The other is to search for small molecules that can induce the same conformational change of Chk1, so that they can be delivered into cancer cells to activate Chk1 molecules. The consequence of either would be permanent cell proliferation inhibition and cancer.


'/>"/>
Contact: Christine A. Somosi
216-368-6287
Case Western Reserve University
Source:Eurekalert

Related medicine news :

1. Even Preschoolers View the Overweight Negatively
2. Catastrophic Head Injuries to High School Football Players Rising
3. That impulsive, moody preschooler may grow up to be a problem gambler
4. Some Schools Dont Let Kids Carry Asthma Inhalers
5. Awards to 5 IU School of Medicine physicians address critical need for geriatricians
6. Excessive sleepiness may be cause of learning, attention and school problems
7. Study: More Pre-Teens Get Vaccines When Middle Schools Require Them
8. A place to play: Researcher designs schoolyard for children with autism
9. Fees Lead Some Kids to Skip After-School Sports: Survey
10. Outstanding high school students receive awards to stimulate research interest in digestive diseases
11. The Tennessee Car Accident Lawyers at Michael D. Ponce & Associates Alert Public of CDC Survey Revealing Majority of High School Seniors Admitting to Texting Behind Wheel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... 24, 2017 , ... Dr. Curry Leavitt, a noted periodontist ... Practice) continuing education (CE) series. As a compassionate and dedicated clinician, Dr. Curry ... numerous CE courses each year. His recent course, Course II of HP3, focused ...
(Date:5/24/2017)... ... May 24, 2017 , ... Medic CE , a Career ... about Pediatric Septic Shock” hosted by the Journal of Emergency Medical Services (JEMS). The ... time, will be presented by Captain Rommie Duckworth, LP, a career fire captain as ...
(Date:5/24/2017)... ... May 24, 2017 , ... If you are thinking of a visit to San ... architecture, October is the perfect time to visit. , Business Architecture Associates is pleased to ... offering for individuals, as a 4-½ day package for individuals, and as 4-½ day corporate ...
(Date:5/24/2017)... ... 24, 2017 , ... Rob Lowe is a sought after actor, and also ... brings the public important topics from all aspects of life, and a new segment ... surrounding feet and ankles. , Podiatry is essential to people’s overall well-being, and if ...
(Date:5/24/2017)... ... May 24, 2017 , ... Fiberstar, Inc., ... for the food and beverage industry offers Citri-Fi®, a natural citrus fiber, to ... purchasing decision process. As a result, labels need to deliver simple, transparent and ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral ... Intellectual Property Office has granted Oramed a patent ... Exenatide". The patent covers Oramed,s invention of an ... is an incretin hormone that stimulates the secretion ...
(Date:5/6/2017)... --  Provista , a proven leader in the supply chain ... Jim Cunniff as the company,s new president and ... to Provista, including most recently serving as the president and ... . He assumed his new role with Provista on May ... Provista," says Jody Hatcher , president, Sourcing and Collaboration ...
(Date:5/4/2017)... May 4, 2017  A recent study published ... Ultraviolet-C light as a means of disinfection ... to reduce bioburden on anesthesia workstations. In the ... high-touch, complex medical equipment surfaces contaminated with three ... "This study further validates the body of ...
Breaking Medicine Technology: